Young Woman with Grade 1 Endometrial Cancer Who Wants to Keep Her Uterus
A 38-year-old nulliparous woman with a body mass index of 42 kg/m² and a 12-year history of polycystic ovary syndrome presents with 6 months of irregular heavy bleeding. Endometrial pipelle biopsy shows grade 1 endometrioid adenocarcinoma. Pelvic magnetic resonance imaging shows a lesion confined to the endometrium with no myometrial invasion and no cervical stromal involvement; CA-125 is 18 U/mL and a chest radiograph is normal. Fasting glucose is 6.4 mmol/L and HbA1c 6.1%. She is in a stable relationship and hopes to conceive within the next 2 years. She asks directly whether the uterus can be kept.
1. Is she a candidate for fertility-sparing management? Set out the eligibility criteria you would apply and the investigations still needed.
Read the worked answer
She may be a candidate - but only after proper staging and pathological review. The combination of grade 1 histology, disease confined to the endometrium, and a strong, time-limited desire for pregnancy fits conservative management. Absolute contraindications are grade 3 disease, deep myometrial invasion, cervical stromal or adnexal involvement, Lynch syndrome, and inability to attend 3-monthly surveillance.
Before starting
- Have the pipelle reviewed by a gynaecological pathologist; pipelle sampling underestimates grade in roughly 15–20% of cases. Hysteroscopic targeted biopsy is preferable.
- MRI or expert ultrasound to confirm no myometrial invasion; computed tomography of the chest if extrauterine disease is suspected.
- Assess for Lynch syndrome (family history; mismatch repair immunohistochemistry) - a positive result changes the entire plan.
- Fertility work-up of both partners, and discussion of oocyte or embryo cryopreservation before high-dose progestin, in case treatment fails.
- Optimise comorbidity: HbA1c, weight, blood pressure; refer to weight-management or bariatric services.
- Explicit consent that this is not standard oncological treatment and that hysterectomy will be needed once childbearing is complete.
A useful framing for the patient: 'We are not choosing the safest cancer operation for you; we are choosing a treatment that gives you a chance of pregnancy, with a small but real risk that the cancer progresses while we try.'
2. She elects conservative treatment. Give the regimen, the surveillance schedule, and the expected outcomes with numbers.
Read the worked answer
Regimen. Megestrol acetate 160–320 mg daily, or medroxyprogesterone acetate 400–600 mg daily, usually combined with a levonorgestrel intrauterine system, which appears to improve response rates and provides endometrial protection. Treat in 3-month blocks with reassessment between blocks.
Surveillance. Endometrial sampling every 3 months (hysteroscopic or office biopsy), plus imaging if symptoms change. Complete response rates for grade 1, stage IA disease are around 70–80%, with a median time to response of 4–6 months. If there is a partial response at 6 months, continuing for a further 3–6 months is reasonable.
Counselling points with numbers
- Recurrence after an initial response is 30–40% over the following years, so surveillance continues even in remission, and completion hysterectomy is advised after family building.
- Progression to higher grade or invasive disease occurs in a minority, but it is precisely why sampling must not be skipped.
- Weight loss of 5–10% independently improves response rates.
- Progestins cause weight gain, mood change and a small venous thromboembolism risk; give thromboprophylaxis advice for immobility and surgery.
- Refer to reproductive medicine as soon as remission is confirmed rather than waiting another year.
Document that she understands the alternative of immediate hysterectomy and has chosen conservative treatment.
3. Twelve months later biopsy shows persistent grade 1 disease with no response. What are the options and how do you counsel her?
Read the worked answer
Persistent disease at 12 months is a decision point, not a personal failure. First establish whether she actually took the progestin, whether the levonorgestrel system is in situ, and whether the histology has upgraded.
Options
- One further 3–6 months of therapy - reasonable only if there was some response, adherence is good and grade is unchanged. Beyond 12 months the chance of response falls substantially.
- Change agent - add a levonorgestrel intrauterine system if not already used, switch the oral agent, add metformin, and intensify weight management.
- Hysterectomy with bilateral salpingo-oophorectomy - definitive, and the correct recommendation if there has been no response at all. Surgical staging is needed because of the risk of occult myometrial invasion.
- Fertility preservation without the uterus - oocyte or embryo cryopreservation before surgery, with surrogacy where lawful, or adoption.
How to say it. Be direct: 'The treatment has had a fair trial and the cancer has not gone away. Continuing carries a risk that it becomes harder to cure.' Offer a joint consultation with gynaecological oncology and reproductive medicine, allow time for reflection, and document the discussion. Do not repeat ineffective treatment indefinitely simply because the patient is reluctant to accept hysterectomy.